… We aim to clarify the concept of biosimilar, from … a literature search on the sites of the
medicines regulatory agencies and PubMed from 1990 to 2014 with the keywords “biosimilars,” “…

… efficacy and safety data on biosimilars. This review summarizes the recent updates on
biosimilars, synthesis, characterization, and current market status. Brief information on the role of …

… To conduct and explore this review, we mainly followed the PRISMA guidelines for systematic
reviews [18], although “state of the art” methodology was also used. To identify relevant …

… explore this review, we mainly followed the PRISMA guidelines for systematic reviews [18], …
Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015…

… efficacy and safety can clearly be deduced from the similarity of physicochemical
characteristics, biological activity/potency, and PK and/or PD profiles of the biosimilar and the RP. …

… The designation of biosimilars is defined in relation to a reference product in an FDA
licensure … The concept of biosimilars: from characterization to evolution— a narrative review. …

… Even though generic drugs and biosimilars are both copies of a reference drug, they differ
… , this short review aims to compare generic drugs and biosimilars in terms of characteristics, …

… or summaries of product characteristics (SmPCs). In Europe, … systematic review of assessment
reports for biosimilars … and that, even for biosimilars referencing the same originator, there …

… during the review period that are of a technical nature and relate to topics such as the
physicochemical and pharmacological characterisation of potential biosimilar medicines. …

… Biosimilars could be a promising option to help decrease healthcare costs and … analysis
on biosimilars. Therefore, we aimed to assess the quantity and quality of worldwide biosimilars …